// App-Quantinova.ai

OT1-02-04 : The DETECT V-study Comparison of dual HER2-targeted therapy with trastuzumab plus pertuzumab in combination with chemo- or endocrine therapy in patients with HER2-positive and hormone-receptor positive metastatic breast cancer

Researchers

Presenter

  • A Polasik

Principal Investigators

  • A Schramm

  • TWP Friedl

  • B Rack

  • E Trapp

  • M Tzschaschel

  • PA Fasching

  • F-A Taran

  • A Hartkopf

  • A Schneeweiss

  • V Müller

  • B Aktas

  • K Pantel

  • F Meier-Stiegen

  • P Wimberger

  • W Janni

  • T Fehm

Medical Centers

  • Dusseldorf, Germany

  • Gynecology and Obstetrics, University Hospital Hamburg-Eppendorf, Hamburg, Germany

  • University Hospital Eppendorf Frauenklinik, Hamburg, Germany

  • Heidelberg University Hospital, Heidelberg, Germany

  • Gynecology and Obstetrics, University Hospital Dresden, Technische Universitat Dresden, Dresden, Germany

  • Gynecology and Obstetrics, University Hospital Tubingen, Tuebingen, Germany

  • Gynecology and Obstetrics, Klinikum der Ludwig-Maximilians-Universitat, Munich, Germany

  • Gynecology and Obstetrics, University Hospital Ulm, Ulm, Germany

  • Gynecology and Obstetrics, University Hospital Tubingen, Tuebingen, Germany

Locations

  • Germany

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Breast cancer

  • Peripheral neuropathy

  • Hand foot syndrome

  • Neutropenia

  • Solid malignancies

Biomarkers

  • Circulating tumor cells

  • Human epidermal growth factor receptor 2

Drug/Treatment

  • Trastuzumab

  • Pertuzumab

Outcome

  • N/A

Study Design

  • randomized

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved